Sarepta Therapeutics (NASDAQ:SRPT) Receives “Market Perform” Rating from William Blair

William Blair restated their market perform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Friday, Marketbeat reports.

Other equities analysts have also recently issued research reports about the company. Jefferies Financial Group reduced their target price on Sarepta Therapeutics from $125.00 to $54.00 and set a “buy” rating on the stock in a report on Monday, June 16th. Royal Bank Of Canada reduced their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a research note on Wednesday, May 7th. Guggenheim decreased their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Needham & Company LLC lowered their target price on shares of Sarepta Therapeutics from $125.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, June 16th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 20th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Hold” and an average target price of $67.64.

Sarepta Therapeutics Price Performance

Shares of SRPT stock opened at $20.08 on Friday. The firm’s 50 day moving average price is $43.10 and its two-hundred day moving average price is $82.89. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. Sarepta Therapeutics has a 52-week low of $18.30 and a 52-week high of $173.25. The stock has a market cap of $1.97 billion, a PE ratio of -7.46 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The company had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. The firm’s revenue for the quarter was up 80.2% on a year-over-year basis. As a group, analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. EP Wealth Advisors LLC lifted its stake in Sarepta Therapeutics by 2.2% in the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock valued at $606,000 after acquiring an additional 105 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 139 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 145 shares in the last quarter. Virtus ETF Advisers LLC lifted its position in shares of Sarepta Therapeutics by 6.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 174 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.